Literature DB >> 10400737

Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax.

Y Koya1, T Ohashi, H Kato, S Hanabuchi, T Tsukahara, F Takemura, K Etoh, M Matsuoka, M Fujii, M Kannagi.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) causes T-cell malignancies in a small percentage of the population infected with the virus after a long carrier state. In the present study, we established a seronegative HTLV-1 carrier state in rats inoculated with a newly established HTLV-1-infected rat T cell line, FPM1. FPM1 originated from rat thymocytes cocultured with a human HTLV-1 producer, MT-2 cells, and expressed rat CD4, CD5, CD25, and HTLV-1 Tax. However, FPM1 scarcely expressed other major HTLV-1 structural proteins and failed to induce typical antibody responses against HTLV-1 in inoculated rats. In contrast, control rats inoculated with MT-2 cells generated significant levels of anti-HTLV-1 antibodies. HTLV-1 proviruses were detected in peripheral blood cells of syngeneic rats inoculated with FPM1 for more than 1 year. Analysis of the flanking region of HTLV-1 provirus integrated into host cells suggested that FPM1 cells remained in these animals over a relatively long period of time. However, a similar seronegative HTLV-1 carrier state was induced in the rats inoculated with mitomycin C-treated FPM1 cells and also in FPM1-inoculated allogeneic rats, suggesting that FPM1 could also transmit HTLV-1 into host cells in vivo. Our findings indicated that (i) HTLV-1-immortalized T cells which preferentially express HTLV-1 Tax persisted in vivo but failed to induce any diseases in immunocompetent syngeneic rats and that (ii) suboptimal levels of HTLV-1 for antibody responses allowed the establishment of persistent HTLV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400737      PMCID: PMC112724     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Adult T-cell leukemia: clinical and hematologic features of 16 cases.

Authors:  T Uchiyama; J Yodoi; K Sagawa; K Takatsuki; H Uchino
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

2.  Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia.

Authors:  S Tamiya; M Matsuoka; K Etoh; T Watanabe; S Kamihira; K Yamaguchi; K Takatsuki
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia.

Authors:  B I Sahai Srivastava; J Minowada
Journal:  Biochem Biophys Res Commun       Date:  1973-04-02       Impact factor: 3.575

4.  Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo.

Authors:  K Etoh; S Tamiya; K Yamaguchi; A Okayama; H Tsubouchi; T Ideta; N Mueller; K Takatsuki; M Matsuoka
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  Induction of chronic inflammatory arthropathy and mesenchymal tumors in rats infected with HTLV-I.

Authors:  J Kira; K Yamasaki; I Yamamoto; H Mizusawa; S Yoshino; S Kusunoki; T Yoshida; Y Koyanagi; Y Tanaka; Y Kawano; M Nakamura; M Tsuneyoshi; N Yamamoto; T Kobayashi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-12-15

6.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

7.  Oral administration of human T-cell leukemia virus type 1 induces immune unresponsiveness with persistent infection in adult rats.

Authors:  H Kato; Y Koya; T Ohashi; S Hanabuchi; F Takemura; M Fujii; H Tsujimoto; A Hasegawa; M Kannagi
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Isolation of human T-cell leukemia virus type I from a transformed T-cell line derived spontaneously from lymphocytes of a seronegative Egyptian patient with mycosis fungoides.

Authors:  M A el-Farrash; H A Salem; M J Kuroda; K Morizono; M Kannagi; S Harada
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies.

Authors:  T Hattori; T Uchiyama; T Toibana; K Takatsuki; H Uchino
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

View more
  14 in total

1.  Transmission of human T-cell lymphotropic virus type 1 tax to rabbits by tax-only-positive human cells.

Authors:  D Zucker-Franklin; B A Pancake; P Lalezari; M Khorshidi
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Rat CRM1 is responsible for the poor activity of human T-cell leukemia virus type 1 Rex protein in rat cells.

Authors:  Y Hakata; M Yamada; H Shida
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response.

Authors:  Atsuhiko Hasegawa; Takashi Ohashi; Shino Hanabuchi; Hirotomo Kato; Fumiyo Takemura; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine.

Authors:  T Ohashi; S Hanabuchi; H Kato; H Tateno; F Takemura; T Tsukahara; Y Koya; A Hasegawa; T Masuda; M Kannagi
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 5.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 6.  HTLV-1 Yin and Yang: Rex and p30 master regulators of viral mRNA trafficking.

Authors:  Hicham H Baydoun; Marcia Bellon; Christophe Nicot
Journal:  AIDS Rev       Date:  2008 Oct-Dec       Impact factor: 2.500

7.  Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model.

Authors:  Takashi Ohashi; Shino Hanabuchi; Reiko Suzuki; Hirotomo Kato; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner.

Authors:  Ryo Takayanagi; Takashi Ohashi; Eizaburo Yamashita; Yohei Kurosaki; Kumiko Tanaka; Yoshiyuki Hakata; Yasumasa Komoda; Satoru Ikeda; Yasuko Tsunetsugu-Yokota; Yuetsu Tanaka; Hisatoshi Shida
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

9.  Human T lymphotropic virus type 1 in a seronegative B chronic lymphocytic leukemia patient.

Authors:  Pinhas Stark; Walter Bodemer; Horst Hannig; Jacob Luboshitz; Matityahu Shaklai; Batya Shohat
Journal:  Med Microbiol Immunol       Date:  2003-01-09       Impact factor: 3.402

10.  Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.

Authors:  Machiko Nomura; Takashi Ohashi; Keiko Nishikawa; Hironori Nishitsuji; Kiyoshi Kurihara; Atsuhiko Hasegawa; Rika A Furuta; Jun-ichi Fujisawa; Yuetsu Tanaka; Shino Hanabuchi; Nanae Harashima; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.